Richard Chin

Adaptive and Flexible Clinical Trials

Buch

CHF 90.00

Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)

Versandfertig innerhalb 1-3 Werktagen

V112: Lieferbar in ca. 10-20 Arbeitstagen

Produktdetails

ISBN: 978-0-367-38247-6
EAN: 9780367382476
Produktnummer: 31837693
Verlag: Taylor and Francis
Sprache: Englisch
Erscheinungsjahr: 2019
Seitenangabe: 198 S.
Masse: H23.4 cm x B15.6 cm 370 g
Abbildungen: Farb., s/w. Abb.
Gewicht: 370

Über den Autor

Richard Chin, M.D. is the Chief Executive Officer of OneWorld Health, a nonprofit pharmaceutical company largely funded by the Bill and Melinda Gates Foundation, developing drugs for impoverished patients in the developing world. Previously, Dr. Chin held multiple senior positions in several biotechnology companies and has extensive expertise in drug development including 10 new drug registrations filings/launches and over 45 Investigational New Drug (IND) Applications. Some of the drugs he has overseen include Rituxan, Lucentis, Tysabri, TNKase, Raptiva, Xolair, Cathflo, Prialt, Protropin, Nutropin, Pulmo- zyme, Azactam, Maxipime, and Bapineuzumab, among others. Dr. Chin was named by Businessweek in 2006 as one of the youngest 99 public company CEOs in the United States. Dr. Chin earned his M.D. from Harvard and the equivalent of a J.D. from Oxford, where he studied as a Rhodes Scholar. Dr. Chin serves as Associate Professor at UCSF School of Medicine and was previously on the adjunct faculty at Stanford University School of Medicine.